Supernus Pharmaceuticals, Inc. reiterated financial guidance for the full year 2024. For the year, the company expects total revenues (includes approximately $125 - $135 million of Trokendi XR and Oxtellar XR) of $580 - $620 million and operating loss of $30 - $0 million.